FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer.

about

Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies.

P2860

Q54988217-4306A217-CBC5-40D8-9114-75A152BCA52F

P2860

FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer.

Item

http://www.wikidata.org/entity/Q42965942

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

FcγRIIA and IIIA polymorphisms ...... ted metastatic gastric cancer.

@en

FcγRIIA and IIIA polymorphisms ...... ted metastatic gastric cancer.

@nl

type

Item

label

FcγRIIA and IIIA polymorphisms ...... ted metastatic gastric cancer.

@en

FcγRIIA and IIIA polymorphisms ...... ted metastatic gastric cancer.

@nl

prefLabel

FcγRIIA and IIIA polymorphisms ...... ted metastatic gastric cancer.

@en

FcγRIIA and IIIA polymorphisms ...... ted metastatic gastric cancer.

@nl

P1476

FcγRIIA and IIIA polymorphisms ...... ated metastatic gastric cancer

@en

P2093

De-Shen Wang

http://www.w3.org/2001/XMLSchema#string

Feng-Hua Wang

http://www.w3.org/2001/XMLSchema#string

Miao-Zhen Qiu

http://www.w3.org/2001/XMLSchema#string

Niu Wang

http://www.w3.org/2001/XMLSchema#string

Rong-Jiao Wang

http://www.w3.org/2001/XMLSchema#string

Si-Mei Shi

http://www.w3.org/2001/XMLSchema#string

Xiao-Li Wei

http://www.w3.org/2001/XMLSchema#string

Yu-Hong Li

http://www.w3.org/2001/XMLSchema#string

Yun-Xin Lu

http://www.w3.org/2001/XMLSchema#string

Zhi-Qiang Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Cancer statistics, 2016

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

Molecular basis for a polymorphism of human Fc gamma receptor II (CD32)

P304

5065-5076

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S142620

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rui-Hua Xu

P577

2017-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29089776

http://www.w3.org/2001/XMLSchema#string

P932

5656338

http://www.w3.org/2001/XMLSchema#string

FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer.

about

P2860

P2860

FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932